Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or New Jersey for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to New Jersey only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. New Jersey (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Hisham El-kadi (NPI 1184698466)

Field	Value
Entity Type	Individual
Organization	Hisham El-kadi
Address	4247 Route 9 N
City	Freehold
State	NJ
ZIP	07728
Taxonomy	Rheumatology Physician
NPI Enumerated	February 14, 2006

Payer Source	Total Paid
Medicare	$3M
Medicaid	$0

Key Findings

This provider is effectively single‑payer in the claims on file: Total Medicare revenue is $3M while Medicaid revenue is none, so all reported public-payer activity is Medicare-driven and the practice’s public revenue exposure is concentrated in that program. Analysts should treat this profile as a Medicare-centric operation for payer-mix planning and benchmarking.

Revenue is highly concentrated in a small set of high-cost injectable drugs: the precomputed top 3 Medicare codes account for 54.5% of Medicare revenue, driven by J0129 ($822.8K, 27.9%), J0897 ($426.6K, 14.5%), and J3262 ($357.1K, 12.1%). This concentration indicates a reliance on a handful of biologic and injectable therapies for the majority of Medicare receipts.

The code mix signals an infusion-heavy rheumatology practice that administers office-based biologics and IV therapies: high-revenue drug codes include J0129 (abatacept), J0897 (denosumab), J3262 (tocilizumab), J1745 (infliximab, $272.5K, 9.2%), and J1602 (golimumab, $226.6K, 7.7%), and the practice also bills infusion/chemotherapy administration codes such as 96413 ($96.7K, 3.3%) and 96401 ($59K, 2.0%). Together these lines point to an operational model that provides on-site infusion/administration rather than purely office consults.

Competitive standing on key drug codes is elevated: J0897 ranks #185 of 10057 providers nationally (98th percentile; extreme outlier), and J0129 ranks #84 of 1221 providers nationally (93th percentile; notably above typical national volume for this code), while J3262 ranks #73 of 618 providers nationally (88th percentile; typical, unremarkable volume for this code). These rank/percentile positions indicate the provider is an outsized national contributor for certain injectable therapies, particularly denosumab and abatacept.

Office visit volume and complexity are also a meaningful revenue driver: 99214 accounts for $268.5K (9.1% of Medicare revenue) and the provider ranks #441 of 479517 providers nationally (100th percentile; extreme outlier) for this code. High 99214 volume combined with significant infusion billing suggests substantial ongoing management of complex, chronic rheumatologic patients in addition to in‑office drug administration.

The practice also reports unusually high procedural volumes for joint and injection procedures, consistent with procedural rheumatology: 20610 is $51.1K (1.7%) and ranks #370 of 39752 providers nationally (99th percentile; extreme outlier), and 20605 is $7.2K (0.2%) and ranks #42 of 5794 providers nationally (99th percentile; notably above typical national volume for this code). These placements indicate above‑typical use of joint injections relative to peers.

The provider bills a mix of adjunct osteoarthritis services and higher-priced intra‑articular products: J7327 (Monovisc) produces $30.9K (1.0%) and J7318 (Durolane) $16.8K (0.6%), while DXA imaging 77080 contributes $7.3K (0.2%). This combination points to a practice offering both imaging for bone health and paid intra‑articular viscosupplementation as ancillary revenue streams.

The NPI was enumerated on 2006-02-14 (~20 years ago), indicating long tenure in the Medicare program; this longevity aligns with the developed infusion and E/M footprint seen in the claims and may reflect an established referral and chronic-care management structure that supports the high-volume biologic administration observed.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

38 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	24,200	$30	$822.8K
J0897	Injection, denosumab, 1 mg	23,700	$20	$426.6K
J3262	Injection, tocilizumab, 1 mg	89,280	$1	$357.1K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	10,480	$30	$272.5K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	2,630	$100	$268.5K
J1602	Injection, golimumab, 1 mg, for intravenous use	20,600	$10	$226.6K
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	52,800	$1	$211.2K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	860	$110	$96.7K
96401	The provider administers nonhormonal, antineoplastic chemotherapy drugs subcutaneously or intramuscularly to the patient.	950	$60	$59K
20610	In this procedure, the provider inserts a needle through the skin of a patient and into a major joint or bursa and then uses the syringe attachment to the needle to remove fluid or he may inject a…	760	$70	$51.1K

Showing 1–10 of 38

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 38 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. New Jersey Distribution

Hisham El-kadi — 11 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — New Jersey

Full comparison — all codes billed, vs. state median

38 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	2	40	7,600	$30	$297K
J3262	4	20	33,800	$1	$227.5K
J0717	22	60	42,300	$1	$219.5K
J1602	6	40	12,580	$10	$165.7K
J1745	2	30	3,670	$30	$131.9K
J0897	6	380	3,060	$20	$87.8K
J7327	38	110	40	$550	$34.1K
96413	6	230	190	$110	$26.6K
99214	10	13,640	130	$90	$23.6K
J7318	12	40	1,920	$10	$13.9K

Showing 1–10 of 38

Related Providers

Other providers that share a Tax Identification Number (TIN) with Hisham El-kadi, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Andrew Sharobeem	AZ	Rheumatology Physician	$2.3M	$0
James Fischkoff	NJ	Rheumatology Physician	$1.1M	$0
Sylwia Sasinowska	FL	Rheumatology Physician	$988.9K	$0

Nearby Providers

Other providers in the same ZIP code as Hisham El-kadi, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Golden Years Care LLC	NJ	Adult Day Care Clinic/Center	$0	$49.5M
Centrastate Medical Center, Inc	NJ	General Acute Care Hospital	$0	$47.4M
Collaborative Support Program Of New Jersey, Inc	NJ	Community/Behavioral Health Agency	$0	$12.2M
Community Care Inc	NJ	Mental Health Clinic/Center (Including Community Mental Health Center)	$0	$11.3M
Tender Smiles 4 Kids Of Monmouth, LLC	NJ	Pediatric Dentistry	$0	$9.5M
Bhavesh Balar	NJ	Hematology & Oncology Physician	$4.2M	$0
Elena Ng	NJ	Ophthalmology Physician	$2.4M	$0
Jeffrey Silberberg	NJ	Hematology & Oncology Physician	$2M	$0
Karabi Sinha	NJ	Anatomic Pathology & Clinical Pathology Physician	$1.9M	$0
Jae Lee	NJ	Radiation Oncology Physician	$970.3K	$0

Hisham El-kadi — Billing Profile & Reimbursement Data

Sign up for Hisham El-kadi — Billing Profile & Reimbursement Data policy alerts

Hisham El-kadi — Billing Profile & Reimbursement Data

Sign up for Hisham El-kadi — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References